ConductScience.org, home

Paper19201650

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.

Cohen EE and 15 others. Lancet Oncol, 2009. Cited by 210 papers, by iCite.

Cite this record

ConductScience Library. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Papers, record 19201650. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19201650

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
PubMed
Journal
Lancet Oncol
PubMed
Year
2009
PubMed
Publication types
Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
210
iCite
Relative citation ratio, by iCite
4.9
iCite
Revised in PubMed
2025-05-29
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Cohen EEEzra E W
2Davis DWDarren W
3Karrison TGTheodore G
4Seiwert TYTanguy Y
5Wong SJStuart J
6Nattam SSreenivasa
7Kozloff MFMark F
8Clark JIJoseph I
9Yan DHDuen-Hwa
10Liu WWen
11Pierce CCarolyn
12Dancey JEJanet E
13Stenson KKerstin
14Blair EElizabeth
15Dekker AAllison
16Vokes EEEverett E

Source PubMed

Download CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antibodies, MonoclonalMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Carcinoma, Squamous CellMajor topic
ErbB ReceptorsMajor topic
Head and Neck NeoplasmsMajor topic
QuinazolinesMajor topic
Vascular Endothelial Growth Factor AMajor topic
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Bevacizumab
Erlotinib Hydrochloride
Female
Humans
Male
Middle Aged
Multivariate Analysis
Regression Analysis
Transforming Growth Factor alpha
Vascular Endothelial Growth Factor Receptor-2

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA014599NCI NIH HHSUnited StatesP30CA014599PubMed and NIHNIH RePORTER
P30 CA14599NCI NIH HHSUnited StatesP30CA014599PubMed and NIHNIH RePORTER
N01-CM-17102NCI NIH HHSUnited StatesPubMedPubMed

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00055913Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck CancerDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in19261251Targeting the future in head and neck cancer.https://conductscience.org/library/papers/19261251

Source PubMed

Download CSV of comments and corrections

References31

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
116954439Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones.Endocr Relat Cancer2006https://conductscience.org/library/papers/16954439PubMed
217704426Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.J Clin Oncol2007https://conductscience.org/library/papers/17704426PubMed
311157032Application of a new multinomial phase II stopping rule using response and early progression.J Clin Oncol2001https://conductscience.org/library/papers/11157032PubMed
416685275Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases.Br J Cancer2006https://conductscience.org/library/papers/16685275PubMed
518784101Platinum-based chemotherapy plus cetuximab in head and neck cancer.N Engl J Med2008https://conductscience.org/library/papers/18784101PubMed
616489018Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors.Cancer Res2006https://conductscience.org/library/papers/16489018PubMed
718045071
Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors.
Curr Cancer Drug Targets2007https://conductscience.org/library/papers/18045071PubMed
810999768
Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
Clin Cancer Res2000https://conductscience.org/library/papers/10999768PubMed
912743152Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.J Clin Oncol2003https://conductscience.org/library/papers/12743152PubMed
1010379698Multinomial phase II cancer trials incorporating response and early progression.J Biopharm Stat1999https://conductscience.org/library/papers/10379698PubMed
1117538161
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
J Clin Oncol2007https://conductscience.org/library/papers/17538161PubMed
1211431346Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.Cancer Res2001https://conductscience.org/library/papers/11431346PubMed
1316299242Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.Clin Cancer Res2005https://conductscience.org/library/papers/16299242PubMed
1415701856Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.Clin Cancer Res2005https://conductscience.org/library/papers/15701856PubMed
1517909199Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.J Clin Oncol2007https://conductscience.org/library/papers/17909199PubMed
1616983506A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers.Invest New Drugs2007https://conductscience.org/library/papers/16983506PubMed
1717429874Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma.Laryngoscope2007https://conductscience.org/library/papers/17429874PubMed
1814701768Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.J Clin Oncol2004https://conductscience.org/library/papers/14701768PubMed
1915908667Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.J Clin Oncol2005https://conductscience.org/library/papers/15908667PubMed
2017876013Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.J Clin Oncol2007https://conductscience.org/library/papers/17876013PubMed

See all 31 referencesDownload CSV of references

Cited by105

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 210 citations.

PMIDTitleJournalYearIn PapersSource
40336633Odontogenic carcinosarcoma: a comprehensive review of clinical and therapeutic insights.Front Oral Health2025https://conductscience.org/library/papers/40336633PubMed
40296503Prospective Pilot Study of Second Primary Tumor Prevention With Erlotinib and Celecoxib in Early-Stage Squamous Cell Carcinoma of the Head and Neck: Long-Term Follow-Up.Head Neck2025https://conductscience.org/library/papers/40296503PubMed
39180066Extracellular vesicle-bound VEGF in oral squamous cell carcinoma and its role in resistance to Bevacizumab Therapy.Cancer Cell Int2024https://conductscience.org/library/papers/39180066PubMed
38414024Bioinformatic analysis and experimental validation of cuproptosis-related LncRNA as a novel biomarker for prognosis and immunotherapy of oral squamous cell carcinoma.Hereditas2024https://conductscience.org/library/papers/38414024PubMed
37686523Advantages of the Combinatorial Molecular Targeted Therapy of Head and Neck Cancer-A Step before Anakoinosis-Based Personalized Treatment.Cancers (Basel)2023https://conductscience.org/library/papers/37686523PubMed
37341071Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma.Cancer Med2023https://conductscience.org/library/papers/37341071PubMed
36646686Targeted therapy for head and neck cancer: signaling pathways and clinical studies.Signal Transduct Target Ther2023https://conductscience.org/library/papers/36646686PubMed
36583766A review of efficacy and safety of cetuximab and bevacizumab-based monoclonal antibodies in head and neck cancer.Med Oncol2022https://conductscience.org/library/papers/36583766PubMed
36245368An integrative approach toward identification and analysis of therapeutic targets involved in HPV pathogenesis with a focus on carcinomas.Cancer Biomark2023https://conductscience.org/library/papers/36245368PubMed
35460943Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-An update on clinical trials.Transl Oncol2022https://conductscience.org/library/papers/35460943PubMed
35158773NSAIDs Overcome PIK3CA Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models.Cancers (Basel)2022https://conductscience.org/library/papers/35158773PubMed
35047986Major Molecular Signaling Pathways in Oral Cancer Associated With Therapeutic Resistance.Front Oral Health2020https://conductscience.org/library/papers/35047986PubMed
34955687Using Patient-Derived Xenografts to Explore the Efficacy of Treating Head-and-Neck Squamous Cell Carcinoma With Anlotinib.Pathol Oncol Res2021https://conductscience.org/library/papers/34955687PubMed
34771633Current and Emerging Molecular Therapies for Head and Neck Squamous Cell Carcinoma.Cancers (Basel)2021https://conductscience.org/library/papers/34771633PubMed
34552581PD-L1-Mediated Immunosuppression in Oral Squamous Cell Carcinoma: Relationship With Macrophage Infiltration and Epithelial to Mesenchymal Transition Markers.Front Immunol2021https://conductscience.org/library/papers/34552581PubMed
34359680Pre-Therapeutic VEGF Level in Plasma Is a Prognostic Bio-Marker in Head and Neck Squamous Cell Carcinoma (HNSCC).Cancers (Basel)2021https://conductscience.org/library/papers/34359680PubMed
34195084Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?Front Oncol2021https://conductscience.org/library/papers/34195084PubMed
34117666Bleeding complications in patients with squamous cell carcinoma of the head and neck.Head Neck2021https://conductscience.org/library/papers/34117666PubMed
33445558Vascular Endothelial Growth Factor: A Translational View in Oral Non-Communicable Diseases.Biomolecules2021https://conductscience.org/library/papers/33445558PubMed
32280512An update on angiogenesis targeting in head and neck squamous cell carcinoma.Cancers Head Neck2020https://conductscience.org/library/papers/32280512PubMed

See all 105 cited byDownload CSV of cited by

Genes13

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
BEVACIZUMABCHEMBL1201583Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1201583ChEMBL
ERLOTINIBCHEMBL553Derived from the trial1https://conductscience.org/library/drugs/CHEMBL553ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19201650

GET https://conductscience.org/api/papers/v1/19201650/references?page=2